PMDA posts notice on proper use of Fiblast Spray 250 and 500 (pharma company request)
「製薬企業からの適正使用等に関するお知らせ」に「フィブラストスプレー250、同スプレー500の適正使用に関するお願い」を掲載しました
Published: 2026-10-05 · Source: Pharmaceuticals and Medical Devices Agency (PMDA) — Safety Updates · Stage: Government Announcement · Area: Healthcare / Pharmaceuticals · Impact (preliminary): Low · First detected by this dashboard: 2026-10-06
View the original Japanese source More Healthcare / Pharmaceuticals updates Search all updates in the dashboard
AI summary
Generated by AI from the Japanese source metadata. It is an unofficial monitoring aid, not legal advice, and may contain errors. The area, stage, and impact labels are preliminary keyword-based triage labels. Confirm every point in the original Japanese source.
Summary
The Pharmaceuticals and Medical Devices Agency (PMDA) added a notice titled 'Request regarding proper use of Fiblast Spray 250 and Fiblast Spray 500' to its 'Notices from pharmaceutical companies on proper use' page. It is a government-site announcement listing a company-issued notice, dated 2026-10-05 per the metadata. The specific content of the request is not included in the provided metadata.
Business Impact
Companies or healthcare providers that handle or use these products may need to check whether the notice's content is relevant to their operations. The practical impact cannot be determined from the provided metadata.
Recommended Action
Review the official PMDA page and the underlying company notice in Japanese to confirm the details and whether they apply to your situation.